<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04689945</url>
  </required_header>
  <id_info>
    <org_study_id>2020-12/898</org_study_id>
    <nct_id>NCT04689945</nct_id>
  </id_info>
  <brief_title>Effects of Analgesia Methods on Vascular Endothelial Growth Factor* and Inflammatory Responses in Breast Cancer Surgery</brief_title>
  <acronym>VEGF</acronym>
  <official_title>Do Analgesic Techniques and Preferences Affect Postoperative Vascular Endothelial Growth Factor and Inflammatory Responses on Breast Cancer Surgery?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Worldwide, breast cancer is the most common cancer among women, and its incidence and&#xD;
      mortality rates are expected to increase significantly in the next years. It remains a major&#xD;
      health problem. There is a vast area on breast cancer and immunity that still needs to be&#xD;
      researched. Do anesthetic techniques and medication preferences effect immune responses? If&#xD;
      so how they effect breast cancer outcomes is unclear.&#xD;
&#xD;
      On this trial, the investigators are searching anesthetic techniques affect on inflammatory&#xD;
      and immune responses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is the most frequently encountered surgery among all cancer surgeries. Although&#xD;
      it is a well known procedure for anesthesiologists, it is still unclear whether&#xD;
      anesthesiology effects immune responses. Cancer therapies often use immune therapies such as&#xD;
      Bevacizumab (a monoclonal antibody which targets Vascular Endothelial Growth Factor),&#xD;
      Trastuzumab(a monoclonal antibody for Herceptin (HER2/Neu) mutation) how anesthetics effect&#xD;
      VEGF stays unclear.&#xD;
&#xD;
      Opioids are commonly used to provide analgesia for cancer pain, and functional opioid&#xD;
      receptors have been identified on natural killer (NK) cells, the lymphocytes responsible for&#xD;
      surveillance and elimination of cancer cells.[4] Anesthesiologists have well founded concerns&#xD;
      about using morphine during cancer surgeries.&#xD;
&#xD;
      Regional anesthetic techniques commonly used on cancer surgeries.The activation of sensory&#xD;
      neurons during pain enhances tumor progression and metastatic potential. Regional anesthesia&#xD;
      blocks somatic nociception and inhibits sympathetic preganglionic outflow (functional&#xD;
      sympathectomy) during surgery. Moreover regional anesthesia, by blocking sympathetic nervous&#xD;
      system output, induces a prevalence of parasympathetic tone. Local anesthetics can also&#xD;
      modulate autonomic receptors. For these reasons, more studies are needed to investigate the&#xD;
      action of regional anesthetic neuromodulation on cancer progression.[11]&#xD;
&#xD;
      The Erector Spinae Plane Block (ESP block) is most often performed on thoracic paraspinal&#xD;
      levels, causes sympathetic blockage. Sympathetic block has been studied on central neuraxial&#xD;
      blocks but the sympathetic block caused by the ESP block and immune responses remain unclear.&#xD;
&#xD;
      Sympathetic block inhibits hyperbolic immune responses after surgery, therefore enhances&#xD;
      postoperative rate of acceleration on cytokine levels. The investigators propose that ESP&#xD;
      block improves immune responses and improved immune responses have better clinical outcomes&#xD;
      for patients with breast cancer. Improved immune responses decrease length of stay (LOS),&#xD;
      enhance postoperative recovery, analgesia and quality of life. Therefore allows better&#xD;
      patient experience about procedures.&#xD;
&#xD;
      The investigators will take 90 patients who will undergo a breast cancer operation and&#xD;
      compare vitals (heart rate, blood pressure, oxygen saturation), Numeric Rating Scales (NRS),&#xD;
      Vascular Endothelial Growth Factor (VEGF) responses, systemic immune inflammatory indexes,&#xD;
      cortisol levels, CRP and Procalcitonin levels between three groups; opioid analgesia&#xD;
      group(group M), ESP block group(group E), non-opioid non-ESP group (group P).&#xD;
&#xD;
      The investigators' main focus is immune alterations after anesthesia techniques.&#xD;
      Anesthesiologist keep track of pain scores after surgery. this trials secondary outcome&#xD;
      focuses on pain management after surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Actual">October 1, 2021</completion_date>
  <primary_completion_date type="Actual">May 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Defining the change in preoperative (baseline), postoperative hour 24 Vascular Endothelial Growth Factor (VEGF) levels between the morphine group (group M), the ESP block group (group E), and the control group (group c).</measure>
    <time_frame>change from baseline VEGF at 24 hours postoperatively</time_frame>
    <description>The investigators will measure VEGF preoperative(baseline), postoperative hour 24 from blood analysis.&#xD;
Normal ranges of serum VEGF were 62-707 pg/ml.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Defining the change in preoperative (baseline), postoperative hour 0, postoperative hour 24 cortisol levels between the morphine group (group M), the ESP block group (group E), and the control group (group c).</measure>
    <time_frame>change from baseline cortisol up to 24 hours postoperatively</time_frame>
    <description>The investigators will measure cortisol preoperative(baseline),postoperative hour 0, postoperative hour 24 from blood analysis.&#xD;
Serum cortisol normal range for adults 8 am to 4pm: 5-25 mcg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Defining the change in preoperative (baseline), postoperative hour 0, postoperative hour 24 C-reactive Protein levels between the morphine group (group M), the ESP block group (group E), and the control group (group c).</measure>
    <time_frame>change from baseline CRP up to 24 hours postoperatively</time_frame>
    <description>The investigators will measure CRP preoperative(baseline), postoperative hour 0, postoperative hour 24 from blood analysis.&#xD;
CRP normal reading is less than 10mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Defining the change in preoperative (baseline), postoperative hour 0, postoperative hour 24 procalcitonin levels between the morphine group (group M), the ESP block group (group E), and the control group (group c).</measure>
    <time_frame>change from baseline procalcitonin up to 24 hours postoperatively</time_frame>
    <description>The investigators will measure Procalcitonin preoperative(baseline), postoperative hour 0, postoperative hour 24 from blood analysis.&#xD;
procalcitonin normal range: 0-0.15 ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Defining the change in preoperative (baseline), postoperative hour 0, postoperative hour 24 systemic immune-inflammatory index levels between the morphine group (group M), the ESP block group (group E), and the control group (group c).</measure>
    <time_frame>change from baseline systemic immune inflammatory index at 24 hours postoperatively</time_frame>
    <description>The investigators will measure systemic immune inflammatory index preoperative(baseline), postoperative hour 0, postoperative hour 24 from blood analysis.&#xD;
Mean value for SII: 459 (189-1168).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Defining the change in preoperative (baseline), postoperative hour 0, postoperative hour 24 neutrophil/lymphocyte ratio (NLR) levels between the morphine group (group M), the ESP block group (group E), and the control group (group c).</measure>
    <time_frame>change from baseline NLR up to 24 hours postoperatively</time_frame>
    <description>The investigators will measure neutrophil/lymphocyte ratio (NLR) preoperative(baseline), postoperative hour 0, postoperative hour 24 from blood analysis.&#xD;
Mean value for the NLR:1.76 (0.83-3.92)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Defining the change in preoperative (baseline), postoperative hour 0, postoperative hour 24 platelet/lymphocyte ratio (PLR) levels between the morphine group (group M), the ESP block group (group E), and the control group (group c).</measure>
    <time_frame>change from baseline PLR up to 24 hours postoperatively</time_frame>
    <description>Defining preoperative (baseline), postoperative hour 0, postoperative hour 24 platelet/lymphocyte ratio (PLR) on patients who undergo breast cancer surgery with the ESP block or morphine analgesia.&#xD;
Mean value for PLR: 120 (61-239)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Defining the change in preoperative (baseline), postoperative hour 0, postoperative hour 24 ferritin levels between the morphine group (group M), the ESP block group (group E), and the control group (group c).</measure>
    <time_frame>change from baseline ferritin up to 24 hours postoperatively</time_frame>
    <description>Defining preoperative (baseline), postoperative hour 0, postoperative hour 24 ferritin levels on patients who undergo breast cancer surgery with the ESP block or morphine analgesia, or control group.&#xD;
The normal range for ferritin: 10-291 mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Defining the change in preoperative (baseline), postoperative hour 0, postoperative hour 24 Lactate dehydrogenase (LDH) levels between the morphine group (group M), the ESP block group (group E), and the control group (group c).</measure>
    <time_frame>change from baseline LDH up to 24 hours postoperatively</time_frame>
    <description>Defining preoperative (baseline), postoperative hour 0, postoperative hour 24 LDH levels on patients who undergo breast cancer surgery with the ESP block or morphine analgesia, or control group.&#xD;
Normal LDH levels range: 140-280 U/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Defining analgesic effects between the morphine group (group M), the ESP block group (group E), and the control group (group c) on patients who had breast cancer surgery.</measure>
    <time_frame>End of surgery up to 24 hours postoperatively</time_frame>
    <description>The investigators will evaluate patients' pain score with numeric rating scale (NRS) postoperative hour 0, 1, 4, 12, 24 and compare NRS between the control group (group c), the ESP block group (group E) and intravenous morphine group (group M)&#xD;
The investigators will compare NRS between two groups at postoperative hour 0, 1, 4,12, 24.&#xD;
The most common form of NRS is a horizontal line with an eleven point numeric range, from 0 (patient with no pain) to 10 (patient with the worst pain possible).</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">91</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Morphine</arm_group_label>
    <description>30 patients who received intravenous morphine intraoperatively, without regional block application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erector Spinae Block</arm_group_label>
    <description>30 patients who had preoperative esp block but did not use morphine during or after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>30 patients who received multimodal analgesia methods other than ESP block or IV morphine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <description>PREOPERATIVE ANALGESIA: None&#xD;
INTRAOPERATİVE ANALGESIA:&#xD;
Paracetamol 1000 mg IV&#xD;
Morphine 0,1 mg/kg IV&#xD;
POSTOPERATIVE ANALGESIA IV Morphine Patient-Controlled Analgesia (PCA) Rescue analgesic: IV paracetamol</description>
    <arm_group_label>Morphine</arm_group_label>
    <other_name>Opioid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Erector Spinae Block</intervention_name>
    <description>PREOPERATIVE ANALGESIA:&#xD;
Ultrasonography (USG) guided ESP block:T4 spinal level, %0,25 concentration 20 ml, single injection&#xD;
INTRAOPERATİVE ANALGESIA:&#xD;
Paracetamol 1000 mg IV&#xD;
dexketoprofen 50 mg IV&#xD;
POSTOPERATIVE ANALGESIA IV PCA with tramadol Rescue analgesic: IV paracetamol</description>
    <arm_group_label>Erector Spinae Block</arm_group_label>
    <other_name>Plane block</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>PREOPERATIVE ANALGESIA: none&#xD;
INTRAOPERATİVE ANALGESIA:&#xD;
Paracetamol 1000 mg IV&#xD;
Dexketoprofen 50 mg IV&#xD;
POSTOPERATIVE ANALGESIA IV PCA with tramadol Rescue analgesic: IV paracetamol</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>other</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators will evaluate unilateral breast cancer patients from Ankara Dr.&#xD;
        Abdurrahman Yurtaslan Oncology Train and Research Hospital who will undergo Mastectomy&#xD;
        procedure.&#xD;
&#xD;
        The investigators will exclude patients who no longer want to participate at any part of&#xD;
        the trial.&#xD;
&#xD;
        3 groups, 30 patients for each group totally 90 patients' data will be collected.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          1. Should be female&#xD;
&#xD;
          2. Should be between 18-65 years old&#xD;
&#xD;
          3. Diagnosed with unilateral primary breast cancer&#xD;
&#xD;
          4. Are decided to have mastectomy surgery&#xD;
&#xD;
          5. Stage 1-2 breast cancer (T0-1-2, N0-1, M0)&#xD;
&#xD;
        Exclusion criteria from the:&#xD;
&#xD;
          1. Being allergic to the anesthetics&#xD;
&#xD;
          2. Previously had breast operation other than diagnostic biopsy&#xD;
&#xD;
          3. Presence of a malignancy history on the other breast&#xD;
&#xD;
          4. Diagnosed with Inflammatory breast cancer&#xD;
&#xD;
          5. Having a risk score of The American Society of Anaesthesiologists (ASA) risk score 3&#xD;
             and above&#xD;
&#xD;
          6. Contraindications for regional block(Allergies for local anesthetics, Anatomic&#xD;
             application difficulties, Coagulopathies)&#xD;
&#xD;
          7. Hormone usage&#xD;
&#xD;
          8. NRS score greater than 3 before the operation&#xD;
&#xD;
          9. Opioid or steroid usage before the operation&#xD;
&#xD;
         10. Rheumatologic history&#xD;
&#xD;
         11. Sickness or drug usage that might cause immunosuppression&#xD;
&#xD;
         12. Chemotherapy and/or radiotherapy history&#xD;
&#xD;
         13. Concomitant history of previous malignancy&#xD;
&#xD;
         14. History of Coronary Artery Disease, Peripheral Vascular Disease that may affect VEGF&#xD;
&#xD;
         15. Chronic smoking&#xD;
&#xD;
         16. Chronic obstructive pulmonary disease&#xD;
&#xD;
         17. Presence of infection at the time of surgery&#xD;
&#xD;
         18. Hypothalamus, Pituitary, adrenal gland dysfunction&#xD;
&#xD;
         19. Autoimmune diseases&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hazal ekin güran aytug, resident</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Abdurrahman Yurtaslan Oncology Train and Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr.Abdurrahman Yurtaslan Ankara Oncology Train and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06200</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Harbeck N, Gnant M. Breast cancer. Lancet. 2017 Mar 18;389(10074):1134-1150. doi: 10.1016/S0140-6736(16)31891-8. Epub 2016 Nov 17. Review.</citation>
    <PMID>27865536</PMID>
  </reference>
  <reference>
    <citation>Bates JP, Derakhshandeh R, Jones L, Webb TJ. Mechanisms of immune evasion in breast cancer. BMC Cancer. 2018 May 11;18(1):556. doi: 10.1186/s12885-018-4441-3. Review.</citation>
    <PMID>29751789</PMID>
  </reference>
  <reference>
    <citation>Sen Y, Xiyang H, Yu H. Effect of thoracic paraspinal block-propofol intravenous general anesthesia on VEGF and TGF-β in patients receiving radical resection of lung cancer. Medicine (Baltimore). 2019 Nov;98(47):e18088. doi: 10.1097/MD.0000000000018088.</citation>
    <PMID>31764844</PMID>
  </reference>
  <reference>
    <citation>Maher DP, Walia D, Heller NM. Morphine decreases the function of primary human natural killer cells by both TLR4 and opioid receptor signaling. Brain Behav Immun. 2020 Jan;83:298-302. doi: 10.1016/j.bbi.2019.10.011. Epub 2019 Oct 15.</citation>
    <PMID>31626971</PMID>
  </reference>
  <reference>
    <citation>Gürkan Y, Aksu C, Kuş A, Yörükoğlu UH, Kılıç CT. Ultrasound guided erector spinae plane block reduces postoperative opioid consumption following breast surgery: A randomized controlled study. J Clin Anesth. 2018 Nov;50:65-68. doi: 10.1016/j.jclinane.2018.06.033. Epub 2018 Jul 2.</citation>
    <PMID>29980005</PMID>
  </reference>
  <reference>
    <citation>Demirci U, Yaman M, Buyukberber S, Coskun U, Baykara M, Uslu K, Ozet A, Benekli M, Bagriacik EU. Prognostic importance of markers for inflammation, angiogenesis and apoptosis in high grade glial tumors during temozolomide and radiotherapy. Int Immunopharmacol. 2012 Dec;14(4):546-9. doi: 10.1016/j.intimp.2012.08.007. Epub 2012 Aug 29.</citation>
    <PMID>22940539</PMID>
  </reference>
  <reference>
    <citation>Sultan SS. Paravertebral block can attenuate cytokine response when it replaces general anesthesia for cancer breast surgeries. Saudi J Anaesth. 2013 Oct;7(4):373-7. doi: 10.4103/1658-354X.121043.</citation>
    <PMID>24348286</PMID>
  </reference>
  <reference>
    <citation>Deegan CA, Murray D, Doran P, Moriarty DC, Sessler DI, Mascha E, Kavanagh BP, Buggy DJ. Anesthetic technique and the cytokine and matrix metalloproteinase response to primary breast cancer surgery. Reg Anesth Pain Med. 2010 Nov-Dec;35(6):490-5. doi: 10.1097/AAP.0b013e3181ef4d05.</citation>
    <PMID>20975461</PMID>
  </reference>
  <reference>
    <citation>Sen S, Koyyalamudi V, Smith DD, Weis RA, Molloy M, Spence AL, Kaye AJ, Labrie-Brown CC, Morgan Hall O, Cornett EM, Kaye AD. The role of regional anesthesia in the propagation of cancer: A comprehensive review. Best Pract Res Clin Anaesthesiol. 2019 Dec;33(4):507-522. doi: 10.1016/j.bpa.2019.07.004. Epub 2019 Jul 31. Review.</citation>
    <PMID>31791567</PMID>
  </reference>
  <reference>
    <citation>Forget P, Aguirre JA, Bencic I, Borgeat A, Cama A, Condron C, Eintrei C, Eroles P, Gupta A, Hales TG, Ionescu D, Johnson M, Kabata P, Kirac I, Ma D, Mokini Z, Guerrero Orriach JL, Retsky M, Sandrucci S, Siekmann W, Štefančić L, Votta-Vellis G, Connolly C, Buggy D. How Anesthetic, Analgesic and Other Non-Surgical Techniques During Cancer Surgery Might Affect Postoperative Oncologic Outcomes: A Summary of Current State of Evidence. Cancers (Basel). 2019 Apr 28;11(5). pii: E592. doi: 10.3390/cancers11050592. Review.</citation>
    <PMID>31035321</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>December 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 30, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Hazal Ekin GÜRAN AYTUĞ. MD</investigator_full_name>
    <investigator_title>Anesthesiology Resident, MD</investigator_title>
  </responsible_party>
  <keyword>erector spinae plane block</keyword>
  <keyword>breast cancer</keyword>
  <keyword>anesthesia and cancer</keyword>
  <keyword>nerve block and cancer</keyword>
  <keyword>cancer prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The investigators will share Study Protocol, Statistical Analysis Plan (SAP), Informed Consent Form (ICF), Clinical Study Report</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will become available starting 6 months from publication.</ipd_time_frame>
    <ipd_access_criteria>IPD will be shared with other clinical experimenters in order to serve as an example to similar studies and to demonstrate the reliability of the study. Consent forms of the participants, preoperative evaluation and postoperative follow-up forms, blood results evaluating inflammatory responses, postoperative analgesia need follow-up form will be open to sharing.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

